See more : NS Tool Co., Ltd. (6157.T) Income Statement Analysis – Financial Results
Complete financial analysis of Vaccinex, Inc. (VCNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaccinex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Gayatri BioOrganics Limited (GAYATRIBI.BO) Income Statement Analysis – Financial Results
- ORIOR AG (0QM6.L) Income Statement Analysis – Financial Results
- Sarcos Technology and Robotics Corporation (STRCW) Income Statement Analysis – Financial Results
- Boralex Inc. (BRLXF) Income Statement Analysis – Financial Results
- Teuza – A Fairchild Technology Venture Ltd. (TEUZF) Income Statement Analysis – Financial Results
Vaccinex, Inc. (VCNX)
About Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 570.00K | 100.00K | 900.00K | 50.00K | 523.00K | 724.00K | 90.00K | 316.00K |
| Cost of Revenue | 0.00 | 207.00K | 169.00K | 2.00K | 199.00K | 1.03M | 160.00K | 115.00K |
| Gross Profit | 570.00K | -107.00K | 731.00K | 48.00K | 324.00K | -309.00K | -70.00K | 201.00K |
| Gross Profit Ratio | 100.00% | -107.00% | 81.22% | 96.00% | 61.95% | -42.68% | -77.78% | 63.61% |
| Research & Development | 16.57M | 13.98M | 17.16M | 21.55M | 25.67M | 22.35M | 16.55M | 16.03M |
| General & Administrative | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Other Expenses | 0.00 | -175.00K | 43.00K | -575.00K | 152.00K | 165.00K | -40.00K | -4.00K |
| Operating Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.34M | 26.97M | 21.03M | 20.46M |
| Cost & Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.54M | 28.01M | 21.19M | 20.58M |
| Interest Income | 0.00 | 2.00K | 809.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00K | 2.00K | 809.00K | 489.00K | 0.00 | 392.00K | 1.36M | 2.99M |
| Depreciation & Amortization | 119.00K | 207.00K | 169.00K | 307.00K | 249.00K | 223.00K | 206.00K | 178.00K |
| EBITDA | -19.75M | -19.61M | -21.40M | -28.06M | -31.61M | -28.90M | -17.20M | -10.78M |
| EBITDA Ratio | -3,464.56% | -19,606.00% | -2,475.33% | -56,110.00% | -6,044.74% | -3,714.50% | -23,264.44% | -6,356.01% |
| Operating Income | -22.89M | -19.91M | -22.49M | -28.33M | -32.02M | -27.28M | -21.10M | -20.26M |
| Operating Income Ratio | -4,014.91% | -19,906.00% | -2,498.89% | -56,662.00% | -6,121.41% | -3,768.09% | -23,448.89% | -6,411.08% |
| Total Other Income/Expenses | 2.63M | 91.00K | 110.00K | -520.00K | 152.00K | -2.24M | 2.35M | 6.32M |
| Income Before Tax | -20.25M | -19.82M | -22.38M | -28.85M | -31.86M | -29.52M | -18.76M | -13.94M |
| Income Before Tax Ratio | -3,552.81% | -19,815.00% | -2,486.67% | -57,702.00% | -6,092.35% | -4,077.07% | -20,843.33% | -4,412.34% |
| Income Tax Expense | 0.00 | -93.00K | 852.00K | 458.00K | 152.00K | -1.85M | 1.28M | 2.99M |
| Net Income | -20.25M | -19.72M | -23.23M | -29.31M | -32.02M | -29.52M | -18.72M | -13.94M |
| Net Income Ratio | -3,552.81% | -19,722.00% | -2,581.33% | -58,618.00% | -6,121.41% | -4,077.07% | -20,802.22% | -4,412.34% |
| EPS | -43.68 | -97.59 | -170.04 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| EPS Diluted | -43.68 | -97.59 | -169.11 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| Weighted Avg Shares Out | 463.65K | 202.08K | 136.63K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
| Weighted Avg Shares Out (Dil) | 463.65K | 202.08K | 137.38K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
Vaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE)...
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer's Disease Conference to be held in Boston on October 24-27, 2023.
Vaccinex, Inc. Announces Reverse Stock Split
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-15 reverse...
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE)...
Fcmi Parent Now Owns 42.8% of Vaccinex
Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. (NASDAQ: VCNX) are charging higher on February 7 on news that the clinical-stage biotechnology company secured a patent. VCNX stock increased by more than 20% in pre-market trading on the news.
7 Penny Stocks To Watch With Big News In February; Time To Buy?
Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?
Why Is Vaccinex (VCNX) Stock Up 67% Today?
Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today's gains come from increased interest from investors.
Source: https://incomestatements.info
Category: Stock Reports